Chapter: New York City Society of Health-system Pharmacists, Western New York Society of Health-system Pharmacists

Topic: **Artificial Intelligence in Pharmacy Practice**

Sponsored by: Yi Guo, Maabo Kludze, Elizabeth Cobb, Amber Johnson, Stephen Eng, Jamie Chin-Hon, Johnny Hon, Tamara Hernandez, Mark Sinnett, Brendan Sorrento, Talisa Marchese

Whereas, Artificial intelligence (AI) ​​​​​​and data integration have proven to be pivotal drivers of change in healthcare over the last several ​​​​years,  

Whereas, Healthcare leaders must balance the risks and benefits of these technologies while safeguarding patient safety, data security, and equity in healthcare delivery, 

Whereas, The appropriate utilization of AI and data integration can contribute to improve patient outcomes and make healthcare more efficient and accessible to all, 

Whereas, Pharmacy practice leaders should foster the development and application of advanced analytics such as AI in activities such as risk assessment, monitoring performance metrics, identifying patients in need of pharmacist care, optimizing medication use, and business management,

Whereas, Pharmacists are uniquely positioned to be key contributors and domain experts in the advancement of AI in healthcare, 

Whereas, Pharmacists should lead the design, implementation, and ongoing ​​evaluation and validation of AI-related applications and technologies that affect medication-use processes and tasks, 

Whereas, ​​Pharmacist should establish standards for the application of AI in the various steps of the medication-use process, including prescribing, reviewing medication orders, and assessing medication-use patterns in populations; therefore be it

**Resolved That:**

The New York State Council of Health-system Pharmacists (NYSCHP) supports pharmacist inclusion in the design, implementation, evaluation, and validation of artificial intelligence-related applications and policies that affect medication-use processes, direct patient care, and patient outcome. NYSCHP advocates for the ethical, regulated, and safe development and use of artificial intelligence in patient care.

Date: 1/18/2024

By:

|  |  |
| --- | --- |
| Name | Signature |
| Yi Guo, PharmD, BCIDP |  |
| Maabo Kludze, PharmD, MBA, BCPS |  |
| Elizabeth Cobb, PharmD |  |
| Amber Johnson, PharmD, MBA, BCSCP |  |
| Stephen Eng, PharmD, BCOP |  |
| Jamie Chin-Hon, PharmD, MS, BCOP |  |
| Johnny Hon, PharmD, BCPS, MBA, DPLA |  |
| Tamara Hernandez, PharmD, MA, MBA, BCPPS |  |
| Mark Sinnett, PharmD, FASHP |  |
| Brendan Sorrento, PharmD, BCPS, BCCP |  |
| Talisa Marchese, PharmD, BCPS, BCPP |  |

**Resources:**

* **ASHP Practice Advancement Initiatives 2030 Recommendations**

<https://www.ashp.org/pharmacy-practice/pai/pai-recommendations?loginreturnUrl=SSOCheckOnly>

* **ASHP Forecast 2024**

<https://academic.oup.com/ajhp/article/81/2/5/7458186>

* **ASHP Statement on the Use of Artificial Intelligence in Pharmacy**

[artificial-intelligence-in-pharmacy.ashx (ashp.org)](https://www.ashp.org/-/media/assets/policy-guidelines/docs/statements/artificial-intelligence-in-pharmacy.ashx?la=en&hash=CD600F3261674788293EAB37074F1352E85CFECA)